DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

Withdrawn

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2016-12-15

Last Posted Date: 2019-04-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02993536

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Circulating Tumor Material in Colorectal Cancer and Melanoma

Completed

Conditions: Colorectal Cancer and Melanoma

Interventions: Other: blood collection

First Posted Date: 2016-09-20

Last Posted Date: 2022-06-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 7

Registration Number: NCT02907086

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain

Not Applicable

Completed

Conditions: Smoking Cessation
Weight Loss

Interventions: Behavioral: SC
Behavioral: BAS+

First Posted Date: 2016-09-20

Last Posted Date: 2024-05-29

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 288

Registration Number: NCT02906787

Locations: 🇺🇸
Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)

Phase 1

Completed

Conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

Interventions: Drug: Galunisertib 150mg by mouth twice a day
Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2016-09-20

Last Posted Date: 2022-03-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 15

Registration Number: NCT02906397

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Ablative Fractional Laser for Sclerotic GVHD-Associated Joint Contractures

Not Applicable

Terminated

Conditions: Subjects With Severe, Refractory Sclerotic Skin Changes

Interventions: Device: CO2 Laser
Radiation: Ultrasound
Diagnostic Test: Skin Biopsy

First Posted Date: 2016-08-26

Last Posted Date: 2020-04-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8

Registration Number: NCT02881047

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Phase 1

Withdrawn

Conditions: Urothelial Cancer

Interventions: Drug: PEMBROLIZUMAB
Radiation: hypofractionated radiation

First Posted Date: 2016-08-26

Last Posted Date: 2019-04-23

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02880345

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2016-07-12

Last Posted Date: 2020-02-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 21

Registration Number: NCT02830282

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma

Withdrawn

Conditions: Melanoma

First Posted Date: 2016-07-11

Last Posted Date: 2020-02-05

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02828345

The Breast Program - Translational Cancer Resource

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2016-06-14

Last Posted Date: 2024-07-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 4000

Registration Number: NCT02798341

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Imaging FDG Flare in Melanoma

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2016-06-07

Last Posted Date: 2024-11-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 21

Registration Number: NCT02791594

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy